This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

GORE® ENFORM Biomaterial Product Study

Sponsored by W.L.Gore & Associates

About this trial

Last updated a year ago

Study ID

ENF 18-06

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 4 years ago

What is this trial about?

A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair). The primary objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on device functional performance.

What are the Participation Requirements?

Pre-procedure Inclusion Criteria:

The subject is / has:

1. At least 18 years old at the time of informed consent. Minimum age required by state
regulations (as applicable).

2. An expected scored Class I (Clean) surgical wound using CDC Surgical Wound
Classification system.

3. A planned implant with GORE® ENFORM Biomaterial for a single site ventral or hiatal
hernia repair as suture line reinforcement.

4. An expected scored Grade 1 or Grade 2 using the Ventral Hernia Working Group Grading
system.

5. Willing to provide informed consent and comply with follow-up requirements.

Pre-procedure Exclusion Criteria:

The subject is / has:

1. Treated in another drug or medical device study within 1 year of study enrollment.

2. Implanted with GORE® ENFORM Biomaterial in the reconstruction of cardiovascular
defects.

3. Hernia repair expected to be performed as part of a bridged procedure (i.e.,
expected inability to perform primary closure of fascia or crura, patients requiring
permanent support from the device).

4. A BMI >40.

5. Evidence of a systemic infection.

6. Cirrhosis or undergoing dialysis.

7. A wound-healing disorder.

8. Immunocompromised such as, with HIV or transplant, or receiving chemo or radiation
therapy.

9. Expected to undergo mesh implantation in conjunction with any bariatric procedure
and / or panniculectomy procedure.

10. A stoma.

11. Co-morbid conditions that may limit their ability to comply with study and follow-up
requirements.

12. Positive pregnancy or lactation status as confirmed by site standard of care.

13. Hernias requiring treatment within multiple body regions or expected use of multiple
hernia mesh devices.

Post-procedure Inclusion Criteria

At the time of index procedure, the subject is / has:

1. At least 18 years old. Minimum age required by state regulations (as applicable).

2. Implanted with GORE® ENFORM Biomaterial for a single site ventral or hiatal hernia
repair as suture-line reinforcement on or before 365 days prior to site protocol
amendment 3 approval date.

3. Unless there is an Informed Consent waiver issued by the Institutional Review Board
(IRB), an Informed Consent Form (ICF) signed by subject.

Post-procedure Exclusion Criteria

At the time of index procedure, the subject is / has:

1. Treated in another drug or medical device study within 1 year of study enrollment.

2. Implanted with GORE® ENFORM Biomaterial in the reconstruction of cardiovascular
defects.

3. Hernia repair that was performed as part of a bridged procedure (i.e., inability to
perform primary closure of fascia or crura, patients requiring permanent support
from the device).

4. A BMI >40.

5. Evidence of a systemic infection.

6. Cirrhosis or undergoing dialysis.

7. A wound-healing disorder.

8. Immunocompromised such as, with HIV or transplant, or receiving chemo or radiation
therapy.

9. Underwent mesh implantation in conjunction with any bariatric procedure and / or
panniculectomy procedure.

10. A stoma.

11. Co-morbid conditions that may limit their ability to comply with study and follow-up
requirements.

12. Positive pregnancy or lactation status as confirmed by site standard of care.

13. Hernias requiring treatment within multiple body regions or expected use of multiple
hernia mesh devices.